Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MCRB Stock Forecast 2026-2027
$5.18
Current Price
$50.16M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MCRB Price Targets
+324.7%
To High Target of $22.00
+228.2%
To Median Target of $17.00
+131.7%
To Low Target of $12.00
MCRB Price Momentum
-15.2%
1 Week Change
-19.8%
1 Month Change
-63.2%
1 Year Change
-65.2%
Year-to-Date Change
-82.7%
From 52W High of $29.98
+2.8%
From 52W Low of $5.04
📊 TOP ANALYST CALLS
Did MCRB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Seres is one of their latest high-conviction picks.
Latest MCRB Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, MCRB has a bullish consensus with a median price target of $17.00 (ranging from $12.00 to $22.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $5.18, the median forecast implies a 228.2% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Keller at HC Wainwright & Co., suggesting a 131.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MCRB Analyst Ratings
2
Buy
0
Hold
0
Sell
MCRB Price Target Range
Low
$12.00
Average
$17.00
High
$22.00
Current: $5.18
Latest MCRB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MCRB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Matthew Keller | Buy | Initiates | $12.00 |
| Mar 13, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Sep 24, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 8, 2025 | Chardan Capital | Neutral | Downgrade | $N/A | |
| Mar 20, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 14, 2025 | Goldman Sachs | Sell | Maintains | $N/A | |
| Nov 14, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 13, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Oct 24, 2024 | JP Morgan | Underweight | Downgrade | $N/A | |
| Sep 13, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 14, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 14, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Jun 7, 2024 | Oppenheimer | Perform | Downgrade | $N/A | |
| Jun 7, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 9, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 8, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 6, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 6, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 16, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Nov 3, 2023 | Goldman Sachs | Sell | Maintains | $N/A |
Seres Therapeutics, Inc. (MCRB) Competitors
The following stocks are similar to Seres based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Seres Therapeutics, Inc. (MCRB) Financial Data
Seres Therapeutics, Inc. has a market capitalization of $50.16M with a P/E ratio of 11.7x. The company generates $1.15M in trailing twelve-month revenue with a -729.4% profit margin.
Revenue growth is -54.6% quarter-over-quarter, while maintaining an operating margin of -5,839.9% and return on equity of -121.9%.
Valuation Metrics
Market Cap
$50.16M
Enterprise Value
$103.44M
P/E Ratio
11.7x
PEG Ratio
-0.1x
Price/Sales
46.0x
Growth & Margins
Revenue Growth (YoY)
-54.6%
Gross Margin
+100.0%
Operating Margin
-5,839.9%
Net Margin
-729.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+59.5%
Current Ratio
1.6x
Debt/Equity
303.8x
ROE
-121.9%
ROA
-38.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Seres Therapeutics, Inc. (MCRB) Business Model
About Seres Therapeutics, Inc.
What They Do
Develops live biotherapeutics for serious diseases.
Business Model
Seres Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development and commercialization of innovative live biotherapeutics targeting serious diseases associated with the human microbiome. The company's focus is on creating treatments that address high-need areas such as bacterial infections and immune disorders, particularly in vulnerable patient populations.
Additional Information
The company is notable for advancing microbiome-based therapeutics and has successfully brought the first FDA-approved oral live biotherapeutic to market. Seres Therapeutics continues to invest in its development pipeline and clinical programs, aiming to address unmet medical needs in transplant medicine and infectious disease prevention.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
66
CEO
Mr. Richard N. Kender B.S., M.B.A.
Country
United States
IPO Year
2015
Website
www.serestherapeutics.comSeres Therapeutics, Inc. (MCRB) Latest News & Analysis
Latest News
Quick Summary
Seres Therapeutics (NASDAQ: MCRB) announced that data from a study on SER-155 indicate its potential as a non-immunosuppressive treatment for gastrointestinal toxicity in cancer patients.
Why It Matters
Seres Therapeutics' positive study results for SER-155 indicate potential market growth and a new treatment avenue for cancer-related gastrointestinal issues, impacting stock performance and investor interest.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Seres Therapeutics (NASDAQ:MCRB) reported positive topline results from a trial of SER-155 for immune-related enterocolitis, with most participants achieving a steroid-free clinical response.
Why It Matters
Positive trial results for SER-155 could indicate strong efficacy, potentially boosting Seres Therapeutics' stock value and attracting investor interest in its future growth and product pipeline.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Seres Therapeutics (MCRB) reported promising clinical trial results for SER-155, targeting immune checkpoint inhibitor-related andropilatis.
Why It Matters
Seres Therapeutics' positive clinical trial results for SER-155 may indicate potential market growth, impacting revenue projections and investor sentiment in biotech stocks.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Seres Therapeutics' SER-155 showed an 80% immunosuppressive-free response in treating diarrhea from irEC in a trial at MSK. The treatment was well tolerated with no serious adverse events reported.
Why It Matters
Positive trial results for SER-155 indicate significant potential to treat irEC without systemic immunosuppression, enhancing its market appeal and growth prospects for Seres Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Seres Therapeutics (Nasdaq: MCRB) will host a webcast to discuss top-line results from a trial of SER-155 for treating immune checkpoint inhibitor-related enterocolitis.
Why It Matters
Seres Therapeutics' webcast on SER-155's trial results highlights potential advancements in cancer treatment, impacting market perception and stock performance for biopharma investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Seres Therapeutics has an agreement with Nestlé Health Science for a $25 million payment in 2026, serving as a buy-out of future VOWST™ net sales milestones.
Why It Matters
The $25 million agreement with Nestlé Health Science secures future cash flow for Seres, reducing uncertainty and enhancing its financial stability, which can positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MCRB Stock
What is Seres Therapeutics, Inc.'s (MCRB) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Seres Therapeutics, Inc. (MCRB) has a median price target of $17.00. The highest price target is $22.00 and the lowest is $12.00.
Is MCRB stock a good investment in 2027?
According to current analyst ratings, MCRB has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MCRB stock?
Wall Street analysts predict MCRB stock could reach $17.00 in the next 12 months. This represents a 228.2% increase from the current price of $5.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Seres Therapeutics, Inc.'s business model?
Seres Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development and commercialization of innovative live biotherapeutics targeting serious diseases associated with the human microbiome. The company's focus is on creating treatments that address high-need areas such as bacterial infections and immune disorders, particularly in vulnerable patient populations.
What is the highest forecasted price for MCRB Seres Therapeutics, Inc.?
The highest price target for MCRB is $22.00 from at , which represents a 324.7% increase from the current price of $5.18.
What is the lowest forecasted price for MCRB Seres Therapeutics, Inc.?
The lowest price target for MCRB is $12.00 from Matthew Keller at HC Wainwright & Co., which represents a 131.7% increase from the current price of $5.18.
What is the overall MCRB consensus from analysts for Seres Therapeutics, Inc.?
The overall analyst consensus for MCRB is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are MCRB stock price projections?
Stock price projections, including those for Seres Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 7:24 AM UTC